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Abstract
Background: Artemisinin-based combination therapy (ACT) is recommended as a means of
prolonging the effectiveness of first-line malaria treatment regimens. Different brands of mefloquine
(MQ) have been reported to be non-bioequivalent; this could result in sub-therapeutic levels of
mefloquine with decreased efficacy. In 2002, mefloquine-artesunate (MQ-AS) combination therapy
was adopted as the first-line treatment for uncomplicated Plasmodium falciparum malaria in the
Amazon region of Peru. Although MQ resistance has yet to be reported from the Peruvian
Amazon, it has been reported from other countries in the Amazon Region. Therefore, continuous
monitoring is warranted to ensure that the first-line therapy remains efficacious. This study
examines the in vivo efficacy and pharmacokinetic parameters through Day 56 of three commercial
formulations of MQ (Lariam®, Mephaquin®, and Mefloquina-AC® Farma) given in combination with
artesunate.
Methods:  Thirty-nine non-pregnant adults with P. falciparum mono-infection were randomly
assigned to receive artesunate in combination with either (1) Lariam, (2) Mephaquin, or (3)
Mefloquina AC. Patients were assessed on Day 0 (with blood samples for pharmacokinetics at 0,
2, 4, and 8 hours), 1, 2, 3, 7, and then weekly until day 56. Clinical and parasitological outcomes
were based on the standardized WHO protocol.
Whole blood mefloquine concentrations were determined by high-performance liquid
chromatography and pharmacokinetic parameters were determined using non-compartmental
analysis of concentration versus time data.
Results: By day 3, all patients had cleared parasitaemia except for one patient in the AC Farma
arm; this patient cleared by day 4. No recurrences of parasitaemia were seen in any of the 34
patients. All three MQ formulations had a terminal half-life of 14–15 days and time to maximum
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plasma concentration of 45–52 hours. The maximal concentration (Cmax) and interquartile range
was 2,820 ng/ml (2,614–3,108) for Lariam, 2,500 ng/ml (2,363–2,713) for Mephaquin, and 2,750 ng/
ml (2,550–3,000) for Mefloquina AC Farma. The pharmacokinetics of the three formulations were
generally similar, with the exception of the Cmax of Mephaquin which was significantly different to
that of Lariam (p = 0.04).
Conclusion:  All three formulations had similar pharmacokinetics; in addition, the
pharmacokinetics seen in this Peruvian population were similar to reports from other ethnic
groups. All patients rapidly cleared their parasitaemia with no evidence of recrudescence by Day
56. Continued surveillance is needed to ensure that patients continue to receive optimal therapy.
Background
The World Health Organization recommends the use of
artemisinin-based combination therapy (ACT) as a means
of prolonging the effectiveness of first-line malarial treat-
ment regimens [1-3]. The effectiveness of ACT relies on
the different modes of action from the partnered drugs.
The artemisinin derivatives, (e.g. artesunate, artemether,
dihydroartemisinin) in the ACT are eliminated rapidly,
while the partner drugs (e.g. mefloquine, amodiaquine,
lumefantrine, piperaquine) are eliminated more slowly.
The artemisinin derivative and its partner drug each pro-
tect against selection for resistance against the other drug
[3]. Therefore, it is important that the non-artemisinin
partner drug maintains consistent pharmacokinetic and
pharmacodynamic properties.
There have been reports of non-bioequivalence of meflo-
quine (MQ) tablets produced from different companies.
For example, in a randomized cross-over study of healthy
volunteers, Weidekamm et al showed a significant differ-
ence in the bioequivalence of Mephaquin® (Mepha) com-
pared with the reference product, Lariam® (Roche), with
Lariam having nearly twice the maximum plasma concen-
tration of Mephaquin (Cmax 1018 ng/ml vs. 656 ng/ml
respectively) and requiring approximately 1/3 of the time
to reach maximum concentration (tmax 13 vs 46 h) when
pharmacokinetic parameters were assessed using plasma
levels of MQ [4]. A study of whole blood MQ levels in
patients with acute uncomplicated falciparum malaria
showed that the relative bioavailability of Eloquine®
(Medochemie Ltd., Cyprus) was only 72% and
Mephaquin only 49% of that of Lariam following admin-
istration of dihydroartemisinin [5]. It is unclear whether
this is clinically relevant [6,7].
In 2002, mefloquine-artesunate (MQ-AS) combination
therapy was adopted as the first-line treatment for uncom-
plicated  Plasmodium falciparum malaria in the Amazon
region of Peru due to increasing failures after treatment
with chloroquine or sulphadoxine-pyrimethamine [8].
Studies done prior to the introduction of MQ-AS in Peru
and other countries in Latin America showed that both
MQ and MQ-AS were highly efficacious; however, these
studies followed patients for only 28 days, as per the
WHO protocol at that time [8-13]. A 28-day follow-up
could underestimate the true failure rate by as much as
40% [14]. Although, MQ resistance has yet to be reported
from the Peruvian Amazon[15], it has been reported from
other countries in the Amazon Region [16-18]. Therefore,
continuous monitoring is warranted to ensure that the
first-line therapy remains efficacious.
Since adoption of MQ-AS as the first-line treatment, MQ
from AC Farma and Mepha have been used routinely in
Peru. The significantly lower bioavailability of
Mephaquine reported by the previous study raised con-
cern that the recommended dose of 25 mg/kg might be
insufficient to achieve therapeutic MQ blood levels in all
patients in Peru. Therefore, the in vivo efficacy and phar-
macokinetic parameters through Day 56 of three commer-
cial tablet formulations of MQ were compared: Lariam,
Mephaquin, and Mefloquine-(AC Farma), when given in
combination with artesunate.
Methods
Patients
The study was conducted between March 2004 and Febru-
ary 2005 at the Hospital de Apoyo, located in the city of
Iquitos, in the Peruvian Amazon region. Patients were
enrolled in five health centers located in the outskirts of
Iquitos. The inclusion criteria for enrolling patients
included: male or non-pregnant female ≥ 18 years of age,
mono-infection with P. falciparum, with a parasite density
between 250 and 50,000 asexual parasites/mm3 as deter-
mined by microscopic examination of a thick blood
smear, fever or history of fever in the previous 48 hours,
informed consent from patient, and a willingness to be
hospitalized for the first 24 hours after initiation of ther-
apy and to return for follow-up visits through day 56.
Patients exhibiting evidence of severe malaria, a history of
an underlying chronic disease or illness that could inter-
fere with the absorption of MQ, a history of hypersensitiv-
ity to MQ, or a history of neuropsychiatric illness or
cardiac conduction problems were excluded.Malaria Journal 2009, 8:58 http://www.malariajournal.com/content/8/1/58
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Eligible patients were assigned to one of three treatment
arms using a list of randomly generated numbers; (1) Lar-
iam (Hoffman-LaRoche Ltd, Basel, Switzerland; 250 mg/
tablet) used as the reference, (2) Mephaquin (Mepha S.A.
Aesch-Basel, Switzerland; 250 mg/tablet), and (3) Meflo-
quina AC (AC Farma Laboratories S.A. Lima, Peru; 250
mg/tablet). All drugs were administered as whole tablets
with water at a dose of 25 mg/kg (15 mg/kg on the first
day and 10 mg/kg on the second day) along with artesu-
nate at a dose of 4 mg/kg/day for three days under super-
vision by clinical staff. No additional food or drink was
given until 2 hours following the administration. Patients
were closely observed for 60 minutes after treatment for
adverse reactions or vomiting. Any patients who vomited
within 60 minutes of the dose were re-dosed with a full
dose, but were excluded from the study. No food was
allowed for two hours after drug administration.
Clinical and laboratory assessments
Patients were assessed on Day 0, 1, 2, 3, 7, and then
weekly until day 56. At each visit patients were questioned
regarding possible adverse effects to mefloquine and
artesunate.
Evaluation of in vivo efficacy
Blood smears were taken by finger prick every day until
negative for parasitaemia and then on days 7, 14, 21, 28,
35, 42, and 56. Thick blood smears were prepared with
Giemsa stain and the number of parasites per 200 WBC
counted. Parasite density was estimated assuming an aver-
age WBC count of 6,000/mm3.
Clinical and parasitological outcomes were based on the
standardized WHO protocol [19]. The adjusted Wald test
was used to calculate the 95% confidence interval [20].
Evaluation of mefloquine pharmacokinetics
Three ml of whole blood for MQ analysis was taken by
venopuncture before administration of the first dose of
MQ and then at 2, 4, 8, 24, 48, and 72 hours and 7, 14,
21, 28, 35, 42, and 56 days. The number of early sampling
times was minimized due to logistical constraints and to
ease patient discomfort. Samples were stored at -20°C
prior to analysis and all samples were analysed within 21
months of collection. MQ concentrations in whole blood
were determined by high-performance liquid chromatog-
raphy using a modified procedure described by Green et al
[21]. The modification involved the use of a 150 × 4.6 mm
octadecylsilica column with a mobile phase consisting of
30% acetonitrile and 70% 0.05 M phosphate buffer (pH =
3) and a flow rate of 1.5 ml/min. Interassay variability was
assessed from 15 standard curve runs of whole blood
spiked with MQ concentrations of 250, 500, 1000, and
2500 ng/ml. Interassay precision (expressed as coefficient
of variation [CV]) was 23%, 20%, 15%, and 2%, respec-
tively while interassay accuracy (CV) was 2%, 4%, -4%,
and 0%, respectively.
Pharmacokinetic parameters for MQ were determined
using non-compartmental analysis of the whole blood
concentration versus time data [22]. The points were plot-
ted and the area-under-the-curve (AUC0→t) from time of
administration to the time of the last quantifiable meas-
urement (Ct) was calculated directly from the log concen-
tration versus time plot using the trapezoidal rule [23].
The AUC from 0 to infinity (AUC) was determined by
combining the AUC0→t with the area extrapolated from
the concentration curve as determined from the concen-
tration of the last quantifiable time divided by the elimi-
nation constant (AUC  = AUC0→t  + C/kel). The last
quantifiable concentration occurred at 1008 hours for
most subjects (>90% for each arm). The slope of the least
squares regression analysis from the last four log concen-
tration-time points was used to determine the terminal
elimination constant (kel) and half life (t1/2 = ln2/kel). The
time at which maximum concentration occurred (tmax),
and the maximum concentration (Cmax) were obtained
directly from fitting the concentration versus time data to
a triexponential model (y = ae-bx + ce-dx + ge-hx) using Sci-
entist™ vers.2.01 curve fitting programme [24]. Cmax and
tmax were determined from the curve maximum from each
plot, therefore no equations were used beside the triexpo-
nential. The parameters were determined from the data
sets collected from individual patients.
Statistical analysis
Statistical analysis was done using SAS Version 9.1.3
(Cary, NC). Fisher's Exact test was used for comparison of
group parameters due to the small group size. The parasite
densities showed a highly skewed distribution; therefore,
they were log-transformed and the Wilcoxon Rank Sum
test was used to test for differences between the densities
after log-transformation. Results were considered statisti-
cally significant with a p-value < 0.05. Based on previous
studies showing that Mephaquin has an AUC and Cmax
approximately one-half that of Lariam, 33 adult patients,
11 of whom are treated with Lariam, 11 with Mephaquin,
and 11 with mefloquine (AC Farma) would be sufficient
to detect a significant difference between the AUC and
Cmax for each of the two formulations and Lariam at a 5%
level of significance and a power of 80%. Since biological
parameters usually do not exhibit a normal distribution
[25], the Mann-Whitney test was used to observe differ-
ences between the test groups relative to the reference
group
Ethics
The study protocol was approved by the institutional
review boards of the US Navy Medical Research Center,
Lima, Peru, Instituto Nacional de Salud del Peru, Lima,Malaria Journal 2009, 8:58 http://www.malariajournal.com/content/8/1/58
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Peru and the Centers for Disease Control and Prevention,
Atlanta, GA, USA. Patients were informed about the study
and enrolled voluntarily after having read and signed the
informed consent document. This study was registered at
ClinicalTrials.gov, number NCT00544024.
Results
Clinical response
Thirty-nine adult subjects ranging in age from 18–61 years
(mean 36 years) were initially enrolled in the study. Sev-
enty-two percent of the patients were male. Each arm ini-
tially consisted of 13 individuals. A total of 5 subjects did
not complete the full follow-up period. One subject was
excluded from the Mephaquin arm on day 1 for hyperten-
sion requiring medication. Two were withdrawn due to
adverse events: one from the Lariam arm on day 5, and
one from the AC Farma arm on D28. Two were lost to fol-
low-up: one from the AC Farma arm on day 35 and one
from the Lariam arm on day 37. Thus, 11, 12, and 11
patients remained for full analysis of efficacy in the Lar-
iam, Mephaquin, and AC Farma arms, respectively. The
three groups were similar with regard to gender, age, and
weight (Table 1). All patients had a history of fever in the
previous 48 hours; 21% of patients had a documented
fever (axillary temperature ≥ 37.5°C) at enrollment. Para-
site density (parasites/mm3) on admission was similar for
each treatment arm [(geometric mean (range)]: Lariam =
8,159 (3,085, 21,578), AC Farma = 4,280 (1,515,
12,088), Mephaquin = 9,224 (3,450, 24,660). There were
no significant differences in the rate of parasite clearance
between treatment arms (Table 2). By day 3, all patients
had cleared parasitaemia except for one patient in the AC
Farma arm; this patient cleared by day 4. No recurrences
of parasitaemia were seen in any of the 34 patients; drug
efficacy was 100%, 95% confidence interval 87.6–100%
for the three arms combined, 69%–100% for Lariam and
AC Farma, and 71%–100% for Mephaquin.
Adverse events
One patient developed insomnia, anxiety and paranoia
after receiving the second dose of Lariam; the drug was
stopped and all symptoms resolved within 24–48 hours.
The symptoms were attributed to mefloquine. No other
drug related adverse events were reported. One patient in
the AC Farma arm was withdrawn (Day 28) following
development of meningoencephalitis, presumed to be
viral. Two other patients in the AC Farma arm had adverse
events deemed unrelated to the study drug and remained
in the study; one developed a subarachnoid haemorrhage
and was hospitalized on study Day 48, the other required
surgery for a traumatic spleen injury on study day 14.
Pharmacokinetics
The pharmacokinetic analysis included all patients who
had remained in the study until at least day 28, and thus
excluded only two patients, one in the Mephaquin arm
and one in the Lariam arm. Figure 1 illustrates the time
versus median whole blood concentrations for the three
tablet formulations. Table 3 shows the pharmacokinetic
parameters for MQ following the administration of Lar-
iam (reference), Mephaquin, and mefloquine-AC Farma
in combination with artesunate to patients diagnosed
with malaria. As the three formulations were not signifi-
cantly different from one another, the overall pharmacok-
inetic parameters were also calculated. The results are
presented as the median with the interquartile range. All
three MQ formulations had a terminal half-life (t1/2) of
14.5–15 days and time to maximum plasma concentra-
tion (tmax) of 45–52 hours. The maximal concentration
(Cmax), expressed as ng/ml was 2,820 (2,614–3,108) for
Lariam, 2,500 (2,363–2,713) for Mephaquin, and 2,750
(2,550–3,000) for Mefloquina AC Farma. The non-para-
metric Mann-Whitney test revealed a significant difference
in the Cmax of Mephaquin relative to the reference (P <
0.05). There were no significant differences (P > 0.05) for
all other parameters between the test and the reference
Table 1: Characteristics of enrolled patients by treatment group
AC farma Lariam Mephaquin
N 13 13 13
Male N (%) 8 (61.5) 9 (69) 11 (84.6)
Age (years) 33.6 35.4 39.5
Fever at enrollment 2 (15%) 3 (23%) 3 (23%)
Days of fever 4.8 5.2 3.7
Geometric Mean Parasite density D0 4279.97 8159.33 9224.15Malaria Journal 2009, 8:58 http://www.malariajournal.com/content/8/1/58
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groups. The coefficient of variation ranged from 16–37%
for Cmax and AUC values.
Discussion
In this study, it was shown that although there is some
manufacturer dependent variation in the drug levels of
MQ, this did not appear to affect clinical outcomes. All
patients rapidly cleared their parasitaemias with no evi-
dence of recrudescence by Day 56. There was also no dif-
ference in occurrence of drug-related side effects between
groups; all formulations were well-tolerated.
All three MQ formulations had a terminal half life (t1/2) of
14–15 days and time to maximum plasma concentration
(tmax) of 45–52 hours. This is similar to previous reports
in the literature [26]; bioequivalence studies for Lariam
conducted by Weidekamm et al [4] and Na-Bangchang et
al [5] reveal t1/2 values of 16 and 11.5 days while tmax val-
ues were 46 and 12 hours, respectively. The tmax values
may have corresponded more closely with Weidekamm et
al [4] because of a more similar dosing schedule. Using
the Mann-Whitney test, there were no differences in val-
ues of AUC, AUC0-t, tmax, and t1/2between the three prod-
ucts. Although a statistically significant difference (P  <
0.05) was observed in the Cmax of Mephaquin relative to
the reference (Lariam, Table 1), no clinically significant
difference could be detected. This group of subjects
tended to be older (median age = 40) than the other arms
(Lariam median age = 32, Mefloquina AC Pharma median
age = 30) and may account for the slower absorbance.
A large relative standard deviation (%RSD) was observed
for the Cmaxand AUCs, ranging from ~16 to 37% for all
formulations. The study design may have contributed to
the high variability since no crossover scheme was
employed and no attempt was made to match patients for
confounding factors, including age, sex, weight, and
degree of parasitaemia. Other studies have also reported
large inter-individual variability (% relative standard devi-
ation = 28–83%) for MQ pharmacokinetic parameters
[5,6,27]. Many drugs may inherently exhibit highly varia-
ble pharmacokinetic parameters, but are generally safe
and efficacious if the therapeutic index is not too narrow.
Midha  et al discusses various approaches to deal with
highly variable drugs [28]. These include the broadening
of acceptance limits based on drug variability, on the
caveat that the interval should be prospectively defined
and justified.
Following introduction of a new anti-malarial drug, it is
important to continue to monitor drug efficacy. Although
many studies use 28-days of follow-up, this length of fol-
low-up may be inadequate for detecting early develop-
ment of resistance. When combinations of drugs with
discordant half-lives, such as mefloquine-artesunate, are
used, the patient, in effect, receives monotherapy with the
longer lasting drug for the tail end of therapy. This may
lead to recrudescence, which may occur more than 4
weeks after administration of drug [29]. It is crucial to
monitor for late treatment failures due to recrudescence
[30-32].
Conclusion
The pharmacokinetics of three formulations of MQ
administered in conjunction with artesunate to patients
with uncomplicated malaria were similar to each other; in
addition, it was shown that they are similar in the Peru-
vian population to that described previously in Southeast
Asian populations. This is the first study to demonstrate
the pharmacokinetics of mefloquine in a South American
population. All three formulations appeared equally effi-
cacious in non-pregnant adults, although the small sam-
ple size precludes a definitive evaluation of efficacy.
Continued surveillance is needed to ensure that patients
continue to receive optimal therapy.
Disclaimer
The views expressed in this article are those of the authors
and do not necessarily reflect the official policy of the
Department of the Navy, Department of Defense, nor the
Table 2: The daily geometric mean parasite density and 95% confidence interval for each treatment group is shown
Parasite density Lariam Mephaquin Mefloquina AC p-value
D0 8159 (3085–21,578) 9224 (3450–24,660) 4280 (1515–12,088) 0.51
D1 40 (7–212) 15 (3–65) 19 (2–131) 0.54
D2 0.38 (0–1.8) 0.48 (0–1.7) 0.88 (0–4.2) 0.86
D3 0 0 0.22 (0–0.87) 0.38
D7 000 1
No statistically significant difference was observed using the Wilcoxon Rank Sum test.Malaria Journal 2009, 8:58 http://www.malariajournal.com/content/8/1/58
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Median whole-blood concentration-time profiles for mefloquine Figure 1
Median whole-blood concentration-time profiles for mefloquine. Mefloquine was administered in a total dose of 25 
mg/kg (15 mg/kg on the first day and 10 mg/kg on the second day) in conjunction with artesunate given at 4 mg/kg/day for three 
days. Figure 1A. shows the whole-blood concentration-time profiles for each formulation separately, while Figure 1B shows the 
curve when all data points were combined. As can be seen, there were no significant differences between the formulations.
A. 
B. Malaria Journal 2009, 8:58 http://www.malariajournal.com/content/8/1/58
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US Government. Some of the authors are military service
members. This work was prepared as part of our official
duties. Title 17 U.S.C. § 105 provides that "Copyright pro-
tection under this title is not available for any work of the
United States Government." Title 17 U.S.C. § 101 defines
a U.S. Government work as a work prepared by a military
service member or employee of the U.S. Government as
part of that person's official duties. The study protocol was
approved by the Naval Medical Research Center institu-
tional review board in compliance with all applicable fed-
eral regulations governing the protection of human
subjects.
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(n = 13)
All
(n = 37)
Cmax (ng/ml) 2820 (2614–3108) 2500 (2363–2713)* 2750 (2550–3000) 2700 (2500–3000)
AUC0→t (mg/ml/day) 59.7 (41–67) 56.1 (51–60) 50.6 (41–67) 56.9 (44–66)
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